Skip to Main Content

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Conditions

Diseases of the Nervous System

Phase II

What is the purpose of this trial?

The purpose of this study is to assess the efficacy, safety, and tolerability profile of CVL-865 as adjunctive treatment in participants with drug-resistant focal onset seizures.

  • Trial with
    Cerevel Therapeutics, LLC
  • Start Date
    07/25/2020
  • End Date
    10/31/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/19/2022
  • Study HIC
    #2000027109